AN2 Therapeutics Inc.
1.23
-0.03 (-2.38%)
At close: Jan 14, 2025, 3:59 PM
1.22
-0.33%
After-hours Jan 14, 2025, 04:30 PM EST
undefined%
Bid 1.22
Market Cap 36.60M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.99
PE Ratio (ttm) -0.62
Forward PE n/a
Analyst Buy
Ask 1.31
Volume 79,207
Avg. Volume (20D) 507,370
Open 1.27
Previous Close 1.26
Day's Range 1.22 - 1.28
52-Week Range 0.87 - 21.55
Beta undefined

About ANTX

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California....

Industry Biotechnology
Sector Healthcare
IPO Date Mar 25, 2022
Employees 41
Stock Exchange NASDAQ
Ticker Symbol ANTX

Analyst Forecast

According to 5 analyst ratings, the average rating for ANTX stock is "Buy." The 12-month stock price forecast is $3.5, which is an increase of 185.71% from the latest price.

Buy 40.00%
Hold 40.00%
Sell 0.00%
Stock Forecasts
5 months ago · Source
-60.98%
AN2 Therapeutics shares are trading lower after th... Unlock content with Pro Subscription
5 months ago · Source
+6.88%
AN2 Therapeutics shares are trading lower after the company announced that it will discontinue its EBO-301 study following topline results from its Phase 2 part of the study in treatment-refractory patients with MAC lung disease.